Cargando…

Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia

The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market. The Food and Drug Administration and European Medicines Agency recently approved the alirocumab and evolocumab, subcuta...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazhar, Faizan, Haider, Nafis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242035/
https://www.ncbi.nlm.nih.gov/pubmed/28163543
http://dx.doi.org/10.4103/0976-500X.195906